Skip to content

SG&A at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$6.03B+18.0%
Amgen logo
AmgenAMGN
$1.6B-5.0%
Exelixis logo
ExelixisEXEL
$139.6M+1.8%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$44.92M+48.6%
AbbVie logo
AbbVieABBV
$3.58B+8.7%
Nuvation Bio logo
Nuvation BioNUVB
$38.31M+8.2%

Other financials

Income statement

See full
Revenue$18.3M+29.5%
Gross profit$18.0M
Operating income-$78.8M-21.8%
Net income-$73.3M-27.7%
EPS (diluted)-$0.83-25.8%

Balance sheet

See full
Cash & equivalents$39.1M-23.8%
Total debt$24.3M+25.4%
Total equity$107.9M-70.4%
Total assets$652.6M-12.3%

Cash flow

See full
Operating cash flow-$85.9M-19.4%
CapEx$128.0K-56.2%
Free cash flow-$86.0M-19.1%

Valuation

See full
Market cap$919.7M+81.6%
Enterprise value$904.89M+90.7%
P/S12.8×+3.5×

Profitability

See full
Operating margin-443.5%+103pp
Net margin-411.2%+125pp
FCF margin130.6%+74.1pp

Returns & leverage

See full
Return on equity-124.7%-252pp
Debt / equity0.2×+0.2×
Current ratio6.1×-1.9×

Where this comes from

Reported directly by Kura Oncology in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kura Oncology's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kura Oncology's SG&A?
Kura Oncology (KURA) reported SG&A of $31.56M in Q1 2026.
How has Kura Oncology's SG&A changed year-over-year?
Kura Oncology's SG&A increased by 38.2% year-over-year, from $22.84M to $31.56M.
What does SG&A mean?
Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.